Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + Docetaxel in mCRPC
NCT04100018Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2020
- Primary completion
- Jun 2023
- Modality
- Monoclonal Antibodies
- Countries
- 28
01
Overview
Phase 3, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Nivolumab + docetaxel + prednisone with Placebo + docetaxel + prednisone (2 arms). Primary endpoints: Radiographic Progression-Free Survival up to 31 months and Overall Survival up to 31 months. Started Feb 2020; status: completed.
02
Drugs
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04100018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04100018.